Shuobo Boboila

Shuobo Boboila

Associate

Patents and Innovations

Dr. Shuobo (Shu) Boboila is an associate in the New York City office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her work focuses on patent prosecution and due diligence matters for clients in the life sciences and biotechnology industries. Shu’s technical expertise includes cellular and molecular biology, cancer therapy, genetics, and pharmacology.

Prior to joining the firm, Shu completed her doctoral and postdoctoral trainings at Columbia University, where she worked on immunotherapy and radiation therapy for treatment of pediatric tumors. She also interned at Columbia Technology Ventures, the technology transfer office for Columbia University.

Experience

Education

J.D., Duke University School of Law, 2022
Postdoctoral Fellowship, Radiation Oncology, Columbia University, 2019
Ph.D., Pathology and Molecular Mechanisms of Diseases, Columbia University, 2015
B.S., Biochemistry, University of Bristol, 2007

Admissions

State Bar of New York
U.S. Patent and Trademark Office

Credentials

Education

J.D., Duke University School of Law, 2022
Postdoctoral Fellowship, Radiation Oncology, Columbia University, 2019
Ph.D., Pathology and Molecular Mechanisms of Diseases, Columbia University, 2015
B.S., Biochemistry, University of Bristol, 2007

Admissions

State Bar of New York
U.S. Patent and Trademark Office

Select Publications

Co-author, “Akt inhibition is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, Her2 receptor negative breast cancer,” 10 Frontiers in Oncology 968, 2020
Co-author, “High-dose radiation increases Notch1 in tumor vasculature,” 106(4) Int J Radiat Oncol Phys. 857-866, 2019
Co-author, “Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma,” 37(40) Oncogene 5451-5465, 2018

Insights

Select Publications

Co-author, “Akt inhibition is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, Her2 receptor negative breast cancer,” 10 Frontiers in Oncology 968, 2020
Co-author, “High-dose radiation increases Notch1 in tumor vasculature,” 106(4) Int J Radiat Oncol Phys. 857-866, 2019
Co-author, “Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma,” 37(40) Oncogene 5451-5465, 2018

Recent Insights

Client Highlights

On February 29, 2024, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Janux from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding the exercise of any pre-funded warrants, are expected to be approximately $296.5 million. In addition, Janux has granted the underwriters a 30-day option to purchase up to an additional 956,450 shares of its common stock. All of the shares to be sold in the offering are to be sold by Janux. The offering is expected to close on or about March 4, 2024, subject to customary closing conditions. Janux intends to use the net proceeds from the offering to advance clinical development of its internal product pipeline and for general corporate purposes.

Learn More

Client Highlights

On November 10, 2023, CARGO Therapeutics, a clinical-stage biotech specializing in cancer treatments, made its debut on the Nasdaq Global Select Market under the ticker "CRGX" after successfully raising approximately $281 million through its initial public offering (IPO). The company priced its IPO at $15 per share, issuing 18.75 million shares. Wilson Sonsini Goodrich & Rosati advised CARGO on patent and technology transactions matters leading up to and with respect to the IPO.

Learn More